Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine vs Vinorelbine in High Risk Breast Cancer with Residual Disease
NCT03703427Phase 2Unknown
- Start
- Nov 2018
- Primary completion
- Nov 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Capecitabine Arm with Vinorelbine Arm (2 arms). Primary endpoint: Disease-Free Survival at 5 years. Status: unknown.
02
Drugs
capecitabinevinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03703427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703427.